Bayer's Q2 Recovery Has a Price Tag: One Courtroom in Missouri Still Decides the Next Chapter
Published on 08/05/2026 at 12:02 | Redaktion boerse-global.de
The numbers were solid, the legal tailwind was real, and the stock responded accordingly. But for Bayer, the second quarter of 2026 was never just about the income statement — it was about drawing a line under a litigation saga that has shadowed the Leverkusen group for years.
The company reported net profit of €219 million for the quarter, reversing a €199 million loss in the same period a year earlier. Adjusted EBITDA came in at €2.14 billion, up 1.9 percent year-on-year and ahead of market expectations. Group revenue rose 2 percent to €10.9 billion, while the first half delivered €24.3 billion in sales, a 3 percent increase, with adjusted EBITDA climbing 7 percent to €6.6 billion. Management reaffirmed its full-year guidance of currency-adjusted sales between €45 billion and €47 billion and adjusted EBITDA of €9.6 billion to €10.1 billion.
Crop Science Carries the Quarter
The engine room was once again the agriculture division. Crop Science saw second-quarter EBITDA jump 30 percent to €902 million on revenue of €4.91 billion, a currency- and portfolio-adjusted gain of 3.5 percent. The rebound was fueled by higher glyphosate prices and the re-approval of Dicamba-based herbicides, which revived US soybean demand. The division posted a 31 percent EBITDA margin for the first half.
Pharma told a more complicated story. Revenue held steady at €4.46 billion, but the composition shifted noticeably. Xarelto, the blood thinner, saw sales fall 42 percent, while eye treatment Eylea dropped 33 percent — both casualties of patent expiries and biosimilar competition. The counterweight came from newer products: cancer drug Nubeqa surged roughly 50 percent to €820 million, and Kerendia also posted strong growth, partially offsetting the declines.
Should investors sell immediately? Or is it worth buying Bayer?
The Legal Clock Is Ticking Toward August 19
For investors, the courtroom calendar may matter more than the earnings release. On June 25, the US Supreme Court ruled 7-2 in the "Durnell" case that federal law preempts state-level claims over missing warning labels, stripping the legal foundation from thousands of glyphosate lawsuits. A US appeals court followed unanimously on August 15, 2024, in the "Schaffner" case, further bolstering Monsanto's position against state warning-label requirements.
The next milestone arrives August 19, when a Missouri court hears arguments on final approval of a proposed $7.25 billion class settlement covering remaining glyphosate claims. The agreement, which would be paid out over 21 years, offers something the market has long craved: a defined cost rather than an open-ended legal exposure. Bayer has also moved to isolate risk operationally, bundling its US glyphosate business into a standalone unit called Ruveon in July.
Debt Reduction Accelerates
The balance sheet is improving faster than previously signaled. Net financial debt stood at €33.65 billion as of June 30, and management has narrowed its year-end target range to €29-30 billion, down from an earlier €32-33 billion corridor. The deleveraging effort has outside help: Apollo is investing €3 billion, and Bayer placed a $5 billion bond. CEO Bill Anderson reiterated that a structural split of the group is not on the agenda, despite speculation — his focus remains on the "Dynamic Shared Ownership" reorganization model and five defined priorities.
Analysts Split on the Risk-Reward
Wednesday's analyst notes capture the divergence in how the market reads this setup. The DZ Bank raised its price target from €54 to €60 with a "Buy" rating, citing operational stabilization and faster debt reduction. UBS is more bullish still, with a "Buy" and a €62 target. JPMorgan kept its "Overweight" stance at €50, pointing to the agriculture division's strong performance.
Jefferies struck a more cautious tone. Analyst Michael Leuchten held his price target at €46 with a "Hold" rating, arguing that the EBITDA beat does not fully offset concerns about the still-elevated debt load.
Bayer at a turning point? This analysis reveals what investors need to know now.
A Stock in Motion
The market's verdict on Tuesday was clear: Bayer shares closed at €48.40, up 2.07 percent, as the DAX hit a record 26,202 points. Wednesday brought another leg up — the stock gained 3.64 percent to €50.16, leaving it 6.87 percent below its 52-week high of €53.86, reached in early July shortly after the Supreme Court ruling. Year-to-date, the shares are up roughly 31 percent.
Technical indicators suggest momentum is building: the relative strength index sits at 64.2, and the stock trades 26.88 percent above its 200-day moving average. Whether that trajectory holds now depends less on quarterly fundamentals and more on what happens in that Missouri courtroom on August 19.
Ad
Bayer Stock: New Analysis - 5 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
